ReWalk RoboticsLFWD
LFWD
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
195% more call options, than puts
Call options by funds: $56K | Put options by funds: $19K
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
10% more funds holding
Funds holding: 21 [Q3] → 23 (+2) [Q4]
4.1% less ownership
Funds ownership: 7.1% [Q3] → 3.0% (-4.1%) [Q4]
67% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 6
77% less capital invested
Capital invested by funds: $2.03M [Q3] → $458K (-$1.57M) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$4
126%
upside
Avg. target
$9
408%
upside
High target
$13
634%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Lake Street Ben Haynor 44% 1-year accuracy 4 / 9 met price target | 126%upside $4 | Buy Maintained | 11 Mar 2025 |
HC Wainwright & Co. Swayampakula Ramakanth 22% 1-year accuracy 45 / 203 met price target | 634%upside $13 | Buy Reiterated | 11 Mar 2025 |
Laidlaw & Co. Yale Jen 50% 1-year accuracy 3 / 6 met price target | 465%upside $10 | Buy Initiated | 10 Feb 2025 |
Financial journalist opinion
Based on 7 articles about LFWD published over the past 30 days
Neutral
Zacks Investment Research
2 weeks ago
Lifeward Stock Falls Despite FDA Clearance of ReWalk 7 Exoskeleton
LFWD secures FDA clearance for its ReWalk 7 Exoskeleton, introducing enhanced features to empower individuals with spinal cord injury and expand mobility options.

Neutral
GlobeNewsWire
2 weeks ago
FDA Issues Clearance for ReWalk 7 Exoskeleton
Seventh Generation of Industry-Leading Exoskeleton Includes New and Enhanced Features for Individuals with Spinal Cord Injury Seventh Generation of Industry-Leading Exoskeleton Includes New and Enhanced Features for Individuals with Spinal Cord Injury

Neutral
Seeking Alpha
3 weeks ago
Lifeward Ltd. (LFWD) Q4 2024 Earnings Call Transcript
Lifeward Ltd. (NASDAQ:LFWD ) Q4 2024 Earnings Conference Call March 7, 2025 8:30 AM ET Company Participants Mike Lawless - CFO Larry Jasinski - CEO Almog Adar - VP, Finance Conference Call Participants Yale Jen - Laidlaw & Company Ben Haynor - Lake Street Capital Markets Swayampakula Ramakanth - H.C.

Negative
Zacks Investment Research
3 weeks ago
Lifeward (LFWD) Reports Q4 Loss, Tops Revenue Estimates
Lifeward (LFWD) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.35 per share a year ago.

Neutral
GlobeNewsWire
3 weeks ago
Lifeward Ltd. Reports Fourth Quarter and Full Year 2024 Financial Results
Record quarterly and annual revenue of $7.5M and $25.7M, respectively Continued strong growth in U.S. pipeline of ReWalk opportunities with over 110 qualified leads in process Strategic s hift t owards p rofitability: 2025 Sustainable Growth Plan f ocuses on growth of c ore p roduct l ines with a s treamlined c ost s tructure and r educed o perating loss MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 07, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd.

Neutral
GlobeNewsWire
3 weeks ago
Lifeward and CorLife Finalize Partnership to Expand Workers' Compensation Access to ReWalk Exoskeleton
CorLife to become the exclusive distributor of the ReWalk Personal Exoskeleton for individuals with Workers' Compensation claims

Neutral
GlobeNewsWire
3 weeks ago
Lifeward and MYOLYN Expand Partnership to Enhance Patient Access to MyoCycle FES Cycling Therapy System for Home Use
New Agreement Expands Distribution Rights to Lifeward to Include Referral Sales for Home Use Applications New Agreement Expands Distribution Rights to Lifeward to Include Referral Sales for Home Use Applications

Neutral
GlobeNewsWire
1 month ago
Lifeward to Report Fourth Quarter and Fiscal Year-End 2024 Financial Results on March 7, 2025
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its fourth quarter and fiscal year-end financial results before the markets open on Friday, March 7, 2025.

Neutral
GlobeNewsWire
1 month ago
Lifeward Announces CEO Transition
CEO Larry Jasinski to Retire Company Begins Search for New Leader to Drive Next Phase of Growth Company Provides Preliminary Full-Year 2024 Revenue Reschedules Virtual Investor Event Until Later in 2025 After Hiring of New CEO MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd.

Neutral
GlobeNewsWire
2 months ago
Lifeward CEO Issues Year-End 2024 Open Letter to Shareholders and Provides 2025 Commercial and Operational Priorities
With recent financing and current capital, the Company believes it has sufficient cash to pursue its goals With recent financing and current capital, the Company believes it has sufficient cash to pursue its goals

Charts implemented using Lightweight Charts™